Abstract 1593P
Background
Adolescent and young adults (AYA) with underlying cancer often experience multiple General Practitioner (GP) consultations before they are referred to a specialist. Certain patient groups may be at higher risk of such events, but evidence is lacking, particularly from Australia. We aimed to examine GP activity prior to cancer diagnosis in an Australian cohort of AYAs and factors associated with multiple GP consultations.
Methods
We conducted an Australian cohort study of patients aged 18–39 years with incident cancer recorded in the Victorian Cancer Registry between 2008-2022 and linkage to the Patron primary care dataset. We calculated the frequency of GP events in the year before cancer diagnosis (GP consultations, prescriptions, blood test and imaging) and the proportion of patients with multiple GP consultations (≥4) in this period. Using multivariable logistic regression models, we examined associations between multiple pre-diagnostic GP consultations and patient characteristics, including age, sex, socioeconomic status, regional or city location, culturally and linguistically diverse background and main spoken language.
Results
1,712 AYAs with cancer were identified: 276 aged 18–25 and 1,436 aged 26–39. AYAs had a mean of 3 GP consults in the six months pre-diagnosis (range 0-46), with 1,035 (60%) AYAs having a GP consultation in this period and 434 AYAs (25%) consulting a GP 4 or more times. AYAs living in regional Australia were more likely to have 4 or more consultations (adjusted odds ratio (AOR) 1.67, 95%CI 1.32-2.10, p<0.001) as were those diagnosed in more recent years, particularly between 2020-2022 (AOR 1.54, 95%CI 1.14-2.07, p=0.005). In AYAs aged 18-25 years, the most deprived patients were more likely to have multiple GP consults (AOR 3.46, 95%CI 1.55-7.72, p=0.002), with no evidence of an association was observed in AYAs aged 26-40.
Conclusions
Our findings identify AYA patient groups at higher risk of multiple GP consultations before cancer diagnosis and at risk of having a prolonged diagnostic journey. These findings could help to inform policy and prioritise early diagnosis interventions focusing on these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Melbourne Human Ethics team in the Office of Research Ethics and Integrity.
Funding
Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10